Cytori Therapeutics Inc Share Price Nasdaq
Stocks
US23283K1051
Biotechnology & Medical Research
| Market Cap | 1.21Cr 1.08Cr 1.01Cr 91.79L 1.73Cr 116.74Cr 1.75Cr 12Cr 4.72Cr 60Cr 4.56Cr 4.46Cr 191.53Cr | P/E 2026 * |
-0.34x | P/E 2027 * | -0.64x |
|---|---|---|---|---|---|
| Enterprise Value | 1.21Cr 1.08Cr 1.01Cr 91.79L 1.73Cr 116.74Cr 1.75Cr 12Cr 4.72Cr 60Cr 4.56Cr 4.46Cr 191.53Cr | EV / Sales 2026 * |
3.26x | EV / Sales 2027 * | 0.63x |
| Free-Float |
98.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| 1 day | -1.85% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 02/04/2014 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 06/02/2020 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 21/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 01/10/2002 |
Richard Hawkins
CHM | Chairman | 77 | 25/01/2018 |
| Director/Board Member | 66 | 01/01/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -29.07% | - | - | 1.21Cr | |
| +4.16% | +3.04% | +49.37% | +94.17% | 7.42TCr | |
| -3.11% | -3.53% | +21.92% | +74.60% | 5.74TCr | |
| +0.89% | -0.63% | +4.28% | +34.51% | 4.76TCr | |
| +0.36% | +0.81% | +352.17% | +689.61% | 4.43TCr | |
| -0.96% | -4.50% | +26.36% | +33.18% | 4.25TCr | |
| -0.20% | -0.77% | +3.74% | +100.60% | 4.07TCr | |
| -0.54% | +2.93% | +9.31% | +50.41% | 3.1TCr | |
| -2.68% | +2.92% | +29.63% | +19.50% | 2.85TCr | |
| +0.05% | -1.64% | -7.28% | -14.06% | 2.43TCr | |
| Average | -0.39% | -0.59% | +54.39% | +120.28% | 4.34TCr | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.77% | +129.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.2L 33.05L 30.84L 28.11L 53.02L 36Cr 53.52L 3.73Cr 1.45Cr 18Cr 1.4Cr 1.37Cr 59Cr | 1.91Cr 1.7Cr 1.59Cr 1.45Cr 2.73Cr 184.01Cr 2.75Cr 19Cr 7.44Cr 94Cr 7.19Cr 7.03Cr 301.9Cr |
| Net income | -3.26Cr -2.9Cr -2.71Cr -2.47Cr -4.65Cr -313.71Cr -4.7Cr -33Cr -13Cr -160.37Cr -12Cr -12Cr -514.69Cr | -1.91Cr -1.69Cr -1.58Cr -1.44Cr -2.72Cr -183.18Cr -2.74Cr -19Cr -7.41Cr -94Cr -7.15Cr -7Cr -300.54Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
